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uate higher their satisfaction from price adequacy. CONCLU-
SIONS: The evaluation of users’ satisfaction from medication as
well as the determination of the factors affecting it should be
incorporated into the third party payers, the pharmaceutical
industry and the Greek government decision making.
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OBJECTIVE: Many Medicare enrolled veterans view the
Department of Veterans Affairs (VA) as a preferred source of
pharmacy services, even when they have access to pharmacy cov-
erage elsewhere. With the implementation of the Medicare phar-
macy beneﬁt imminent, the objective of these analyses was to
examine how one alternative source of pharmacy care, Medicare
managed care (HMO) enrollment, affects the use of VA phar-
macy services. METHODS: We combined national calendar year
(CY) 2002 Medicare enrollment data for Medicare-enrolled VA
users with pharmacy cost records from the VA’s national Deci-
sion Support System (DSS) ﬁles. VA users were identiﬁed as a
Medicare HMO enrollee if they were enrolled in a Medicare
HMO at any time during CY 2002. RESULTS: In CY 2002, 2.3
million Medicare enrolled veterans (5.4% of all Medicare bene-
ﬁciaries) received medications from the VA, at a total cost of $2.4
billion (68% of all VA pharmacy costs). Across the 127 individ-
ual VA medical centers (VAMCs) there was wide variation in the
percentage of HMO enrollees among Medicare enrolled phar-
macy users (from <1% to >49%) and in the percentage of phar-
macy costs associated with their use (from <1% to >41%). HMO
enrollees were just as likely as non-enrollees to use VA pharmacy
care, although the average annual cost of their care was lower—
$847 per year [sd = $1969] versus $1101 [$2794] for non-
enrollees (p £ 0.0001). CONCLUSIONS: VA users who are
enrolled in Medicare HMOs continue to use VA pharmacy ser-
vices, even though the large majority of them have access to
pharmacy coverage through their HMO plans. Although the
implementation of the Medicare prescription drug beneﬁt in
2006 is expected to increase access to prescription drugs for
Medicare beneﬁciaries, the VA will likely remain a signiﬁcant
pharmacy provider for Medicare enrolled veterans.
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OBJECTIVES: To provide a comprehensive and systematic
review of the literature on medical tourism and health tourism,
to present a grounded conceptual model for the constructs and
to provide a historical background on the matter. METHODS:
“Medical tourism” and “health tourism” were separately
searched using the Medline database to review the literature on
the availability and use of the terms. Given the limited results
for both terms, the broader term “tourism” was searched.
Entries referring to a type of tourism were investigated further
for classiﬁcation of the variants of tourism and to understand
their nature and context of use in the ﬁeld. RESULTS: The
Medline search for “medical tourism” generated only nine
results while the term “health tourism” produced 15 results. The
term “tourism” produced 445 entries 177 of which were non-
English; all languages were considered in the abstract review. Of
the 445 entries, 58 types of tourism and four categories were
generated with “well-being” as main reference for the grounded
conceptual model. Analysis of the results revealed that an explicit
deﬁnition for either term is the exception rather than the rule
and that the two terms are treated as similar concepts. CON-
CLUSION: The review of the literature underlined the problem
of a severely limited literature and the lack of consensus on def-
initions and clarity on the conceptual framework. This paper
deﬁned health tourism as travel outside one’s local environment
for the maintenance, improvement or restoration of the individ-
ual’s well-being in mind and body while medical tourism, a
subset of the health tourism is travel outside one’s natural health
care jurisdiction for the improvement or restoration of the indi-
vidual’s well-being in mind and body. This overview has pre-
sented that as a matter of history, the concept of health tourism
and medical tourism is not new.
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OBJECTIVES: Governmental price regulation of drugs has
become a popular measure to contain health care spending. The
aim is to evaluate the effectiveness of selected demand and supply
side measures, keeping in mind crucial factors in this market, for
instance the free rider problem and moral hazard. METHODS:
To analyze reference price limits on reimbursement a static two
class product model is introduced. Beside this measure addi-
tionally patents, parallel imports as supply side price regulation
and drug budget for physicians and generic drugs as demand side
price regulation will be reviewed. RESULTS: By using a sequen-
tial price-setting process within the model it can be shown that
applying marginal cost pricing for drugs clustered within Phase
1, welfare can be increased. If government sets the reference price
equal to the marginal costs welfare can be increased without free
riding on the sunk R&D costs of researching pharmaceutical
ﬁrms because the patent protection has expired. To give a com-
prehensive evaluation of the other pricing policies the interac-
tions between regulative measures are taken into account.
CONCLUSIONS: In the past too many regulative measures to
contain health care expenditures have been targeted primarily to
supply side measures or to demand side measures. But, regula-
tion that only applies on one side does little to control the rising
expenditures. Without simultaneous use of demand side incen-
tives and volume controls, pharmaceutical expenditures proba-
bly can not be reduced effectively.
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OBJECTIVES: To review the three national bodies responsible
for health technology assessment in the UK: the National Insti-
tute for Health and Clinical Excellence (NICE), the Scottish
Medicines Consortium (SMC) and the All Wales Medicines Strat-
egy Group (AWMSG); to judge their ﬁtness for purpose; and to
assess the value of a multi-layered system. METHODS: The
working of the organisations was classiﬁed under four headings:
objectives and scope; assessment of technologies; the decision
process; implementation. The main source of information was
the documentation produced by these bodies on their rules,
